Early Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with prostate cancer confirmed by a pathologist, with a Gleason score of 6 or higher (a measure of how the cancer cells look under a microscope).
• People whose prostate cancer is considered removable by surgery, and who already have a planned surgery to remove the prostate (called a radical prostatectomy).
• People who have enough tissue remaining from their original prostate biopsy for the study's laboratory tests, without using up what is needed for regular medical care.
• People aged over 18 years.
• People whose blood counts, liver function, and kidney function meet specific minimum levels before entering the study (including healthy red and white blood cell counts, platelet levels, liver enzyme levels, and kidney filtration rates within required ranges).
• People who are considered medically well enough to undergo surgery to remove the prostate.
• People with any eye condition affecting the retina may only be considered for the trial if an eye specialist (ophthalmologist) gives their approval.
• People who have been fully informed about the investigational nature of the study and have given written consent before any study procedures begin.

Who may not be able to join:

• People who have previously received radiation therapy for their prostate cancer.
• People who have previously received chemotherapy for their prostate cancer.
• People who have digestive or bowel problems that prevent them from swallowing medication, require feeding through a vein, or who have had major bowel surgery or conditions that affect how the body absorbs food (such as Crohn's disease, ulcerative colitis, or bowel removal surgery).
• People who have a serious uncontrolled medical condition or an active infection that could interfere with receiving the study treatment.
• People with significant heart problems, including uncontrolled high blood pressure, unstable chest pain (angina), heart failure, a heart attack in the past 3 months, serious irregular heart rhythms, a specific heart electrical measurement (corrected QT interval) of 450 ms or more, or a history of a dangerous heart rhythm called Torsade de pointes.
• People with dementia or a significantly reduced mental capacity that would prevent them from understanding the study or giving informed consent.
• People currently taking medications known as disease-modifying anti-rheumatic drugs (DMARDs), which are used to treat conditions like rheumatoid arthritis.
• People with a known or past diagnosis of a genetic condition called G6PD deficiency, or people assessed by the treating doctor as being at increased risk for this condition, unless a screening test has come back negative (confirm with trial site).
• People currently taking certain commercially available medications — specifically calcitriol or chloroquine — that may affect a cell process called autophagy.
• People regularly taking medications known to cause a specific dangerous heart rhythm (Torsade de pointes), unless those medications can be stopped for long enough before joining the study (confirm with trial site).
• People with poorly controlled diabetes.
• People with a history of epilepsy.
• People with a history of a condition called porphyria (a rare disorder affecting the body's production of a substance called porphyrin).

Important: Always verify eligibility with the trial site directly before applying.